title: Incorporating founder virus information in vaccine field trials.
abstract: Vaccine clinical trials with active surveillance for infection often use the time to infection as the primary endpoint. A common method of analysis for such trials is to compare the times to infection between the vaccine and placebo groups using a Cox regression model. With new technology, we can sometimes additionally record the precise number of virions that cause infection rather than just the indicator that infection occurred. In this article, we develop a unified approach for vaccine trials that couples the time to infection with the number of infecting or founder viruses. We assume that the instantaneous risk of a potentially infectious exposure for individuals in the placebo and vaccine groups follows the same proportional intensity model. Following exposure, the number of founder viruses X* is assumed to be generated from some distribution on 0,1,…, which is allowed to be different for the two groups. Exposures that result in X*=0 are unobservable. We denote the placebo and vaccine means of X* by μ and μΔ so that 1-Δ measures the proportion reduction in the mean number of infecting virions due to vaccination per exposure. We develop different semi-parametric methods of estimating Δ. We allow the distribution of X* to be Poisson or unspecified, and discuss how to incorporate covariates that impact the time to exposure and/or X*. Interestingly Δ, which is a ratio of untruncated means, can be reliably estimated using truncated data (X*>0), even if the placebo and vaccine distributions of X* are completely unspecified. Simulations of vaccine clinical trials show that the method can reliably recover Δ in realistic settings. We apply our methods to an HIV vaccine trial conducted in injecting drug users.
authors.affiliation: Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, 6700B Rockledge Drive MSC 7609, Bethesda, Maryland 20892, U.S.A.
authors.forename: Dean
authors.initials: D
authors.lastname: Follmann
authors.affiliation: Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 550 N. Broadway, Baltimore, Maryland 21205, U.S.A.
authors.forename: Chiung-Yu
authors.initials: CY
authors.lastname: Huang
mesh_terms: D016915:AIDS Vaccines / Q000494:pharmacology; D019883:Alkyl and Aryl Transferases; D001699:Biometry; D003198:Computer Simulation; D003576:Electron Transport Complex IV; D015658:HIV Infections / Q000517:prevention & control / Q000821:virology; D006801:Humans; D008565:Membrane Proteins; D015233:Models, Statistical; D016012:Poisson Distribution; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D014765:Viral Vaccines / Q000494:pharmacology*; D014777:Virus Diseases / Q000517:prevention & control / Q000821:virology
chemical_list: D016915:AIDS Vaccines; D008565:Membrane Proteins; D014765:Viral Vaccines; C490115:COX10 protein, human; D003576:Electron Transport Complex IV; D019883:Alkyl and Aryl Transferases
keywords: Burden of illness; Competing risks; Cox regression; Empirical process; Infectious disease; Marked process